Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Assenagon Asset Management S.A.
03:24am, Friday, 19'th Dec 2025
Assenagon Asset Management S.A. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 354.5% during the third quarter, according to its most recent disclosure with the Se
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing faci
Is Alnylam Entering A Corrective Phase After A Strong Run?
07:04am, Tuesday, 16'th Dec 2025
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens o
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
06:01am, Monday, 15'th Dec 2025
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
07:00am, Thursday, 11'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately neg
Federated Hermes Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY
05:03am, Monday, 08'th Dec 2025
Federated Hermes Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 22.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and
Is Alnylam Pharmaceuticals a Millionaire Maker?
02:25am, Sunday, 07'th Dec 2025
Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.
Alnylam Pharmaceuticals Announces Changes to Board of Directors
08:00am, Wednesday, 03'rd Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of tw
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing
03:47pm, Monday, 01'st Dec 2025
Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.
American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades
09:23am, Sunday, 30'th Nov 2025
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarte
What's Going On With Alnylam Stock On Friday?
12:42pm, Friday, 28'th Nov 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.
Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review
01:38pm, Wednesday, 26'th Nov 2025
The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) wer
S&P 500 Retailer Leads Five Resilient Stocks After Nvidia-Led Market Sell-Off
08:00am, Saturday, 22'nd Nov 2025
The S&P 500's TJX is among the five stocks to watch showing resilience in a tough market
UK's drug-cost watchdog recommends Alnylam's heart disease drug
07:09pm, Thursday, 20'th Nov 2025
The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the compa
Catalyst Funds Management Pty Ltd Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
04:42am, Thursday, 20'th Nov 2025
Catalyst Funds Management Pty Ltd reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 43.9% in the second quarter, according to its most recent disclosure with the Securities and E
